LOS ANGELES--(BUSINESS WIRE)--Aug. 17, 2006--Avantogen Oncology, Inc. (OTCBB:AVTO) today announced preliminary results from a phase I dose ranging study evaluating different doses of RP101 in combination with gemcitabine chemotherapy in patients with advanced pancreatic cancer.
